M G Rumi

Summary

Affiliation: University of Milan
Country: Italy

Publications

  1. ncbi Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C
    M Rumi
    Hepatology Unit, San Giuseppe Hospital, Universita degli Studi di Milano, Milan, Italy
    J Viral Hepat 19:37-41. 2012
  2. ncbi Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study
    Maria Grazia Rumi
    AM Et A Migliavacca Centre for Liver Disease, Division of Gastroenterology, Fondazione IRCCS Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    Antivir Ther 12:1033-40. 2007
  3. ncbi Progressive hepatic fibrosis in healthy carriers of hepatitis C virus with a transaminase breakthrough
    M G Rumi
    Division of Hepatology, Antonio e Angela Maria Migliavacca Center for Liver Disease and Fondazione Italiana Ricerca Cancro, Liver Cancer Unit, Ospedale Maggiore IRCCS and University of Milan, Italy
    J Viral Hepat 9:71-4. 2002
  4. ncbi Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C
    Maria Grazia Rumi
    AM Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Maggiore Hospital, Mangiagalli e Regina Elena, Universita degli Studi di Milano, Milan, Italy
    Gastroenterology 138:108-15. 2010
  5. ncbi Hepatitis C virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy
    M E Mancuso
    Department of Medicine and Medical Specialities, Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation, Milan, Italy
    J Thromb Haemost 7:1997-2005. 2009
  6. ncbi Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin
    L Valenti
    Department of Internal Medicine, Universita degli Studi, Fondazione Cà Granda IRCCS Ospedale Maggiore Policlinico, Milan, Italy
    Aliment Pharmacol Ther 35:1434-42. 2012
  7. ncbi Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients
    M G Rumi
    AM and A Migliavacca Centre for the Study of Liver Disease and Department of Gastroenterology and Endocrinology, IRCCS Maggiore Hospital and University of Milan, Milan, Italy
    Gut 54:402-6. 2005
  8. ncbi Recovery after L-DOPA treatment in peginterferon and ribavirin induced parkinsonism
    A Bersano
    Department of Neurological Sciences Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, 7 IRCCS, Via F Sforza 35, Universita degli Studi di Milano, Milano, Italy
    Eur J Intern Med 19:370-1. 2008
  9. ncbi Hepatitis C in haemophilia: lights and shadows
    M G Rumi
    Department of Gastroenterology and Endocrinology, A. Bianchi Bonomi Thrombosis Center, IRCCS Maggiore Hospital, University of Milan, 20122 Milan, Italy
    Haemophilia 10:211-5. 2004
  10. ncbi Sustained suppression of hepatitis C virus by high doses of interferon and ribavirin in adult hemophilic patients
    E Santagostino
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and the Division of Hepatology, IRCCS Maggiore Hospital, University of Milan, Milan, Italy
    Transfusion 44:790-4. 2004

Collaborators

Detail Information

Publications13

  1. ncbi Comparative trials of peginterferon α2a and peginterferon α2b for chronic hepatitis C
    M Rumi
    Hepatology Unit, San Giuseppe Hospital, Universita degli Studi di Milano, Milan, Italy
    J Viral Hepat 19:37-41. 2012
    ..Retrospective cohort studies and randomized prospective head-to-head trials have attempted to resolve the considerable controversy over this issue and support evidence-based treatment decisions...
  2. ncbi Lack of rapid virological response predicts interferon-alpha2b/ribavirin therapy failure in HCV genotype 2 patients: a single-centre study
    Maria Grazia Rumi
    AM Et A Migliavacca Centre for Liver Disease, Division of Gastroenterology, Fondazione IRCCS Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy
    Antivir Ther 12:1033-40. 2007
    ..The analysis of 'real-life' HCV-2 patients might help define the effectiveness of anti-HCV therapy and the role of response moderators...
  3. ncbi Progressive hepatic fibrosis in healthy carriers of hepatitis C virus with a transaminase breakthrough
    M G Rumi
    Division of Hepatology, Antonio e Angela Maria Migliavacca Center for Liver Disease and Fondazione Italiana Ricerca Cancro, Liver Cancer Unit, Ospedale Maggiore IRCCS and University of Milan, Italy
    J Viral Hepat 9:71-4. 2002
    ..Hence, extended surveillance of HCV carriers with consistently normal or minimally elevated ALT values is warranted as these patients are at risk of ALT flares and may develop progressive liver disease...
  4. ncbi Randomized study of peginterferon-alpha2a plus ribavirin vs peginterferon-alpha2b plus ribavirin in chronic hepatitis C
    Maria Grazia Rumi
    AM Migliavacca Center for Liver Disease, First Division of Gastroenterology, Fondazione IRCCS Maggiore Hospital, Mangiagalli e Regina Elena, Universita degli Studi di Milano, Milan, Italy
    Gastroenterology 138:108-15. 2010
    ..Due to the lack of head-to-head studies, the 2 PegIFNs have not been directly compared. The endpoints of our study were safety and antiviral efficacy of the 2 regimens...
  5. ncbi Hepatitis C virus/human immunodeficiency virus coinfection in hemophiliacs: high rates of sustained virologic response to pegylated interferon and ribavirin therapy
    M E Mancuso
    Department of Medicine and Medical Specialities, Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, IRCCS Maggiore Hospital, Mangiagalli and Regina Elena Foundation, Milan, Italy
    J Thromb Haemost 7:1997-2005. 2009
    ..OBJECTIVES AND PATIENTS: In this open-label, prospective, multicenter study, the efficacy and safety of therapy with Peg-IFNalpha2a plus Rbv was evaluated in 34 HCV/HIV-coinfected adult hemophiliacs naive to previous antiviral therapy...
  6. ncbi Implications of PNPLA3 polymorphism in chronic hepatitis C patients receiving peginterferon plus ribavirin
    L Valenti
    Department of Internal Medicine, Universita degli Studi, Fondazione Cà Granda IRCCS Ospedale Maggiore Policlinico, Milan, Italy
    Aliment Pharmacol Ther 35:1434-42. 2012
    ..Homozygosity for the PNPLA3 p.I148M polymorphism influences steatosis and fibrogenesis in chronic hepatitis C (CHC)...
  7. ncbi Hepatitis C reactivation in patients with chronic infection with genotypes 1b and 2c: a retrospective cohort study of 206 untreated patients
    M G Rumi
    AM and A Migliavacca Centre for the Study of Liver Disease and Department of Gastroenterology and Endocrinology, IRCCS Maggiore Hospital and University of Milan, Milan, Italy
    Gut 54:402-6. 2005
    ....
  8. ncbi Recovery after L-DOPA treatment in peginterferon and ribavirin induced parkinsonism
    A Bersano
    Department of Neurological Sciences Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, 7 IRCCS, Via F Sforza 35, Universita degli Studi di Milano, Milano, Italy
    Eur J Intern Med 19:370-1. 2008
    ..IFN-based therapy has been associated with high rates (20%) of central nervous system side effects, but only a few case reports exist on extrapyramidal side effects...
  9. ncbi Hepatitis C in haemophilia: lights and shadows
    M G Rumi
    Department of Gastroenterology and Endocrinology, A. Bianchi Bonomi Thrombosis Center, IRCCS Maggiore Hospital, University of Milan, 20122 Milan, Italy
    Haemophilia 10:211-5. 2004
    ..The development of newer interferon-based therapies provides an opportunity for modifying the natural history of HCV infection in a substantial number of haemophilic patients...
  10. ncbi Sustained suppression of hepatitis C virus by high doses of interferon and ribavirin in adult hemophilic patients
    E Santagostino
    Angelo Bianchi Bonomi Hemophilia and Thrombosis Center and the Division of Hepatology, IRCCS Maggiore Hospital, University of Milan, Milan, Italy
    Transfusion 44:790-4. 2004
    ..35%). CONCLUSIONS: High-dose IFN therapy plus ribavirin provided high rates of sustained virologic responses in adult hemophiliacs with chronic HCV, even if side-effects led to dose reduction in half of these patients...
  11. ncbi High prevalence, low pathogenicity of hepatitis G virus in kidney transplant recipients
    F De Filippi
    Angela Maria e Antonio Migliavacca Center for Liver Disease, Department of Internal Medicine, IRCCS Maggiore Hospital, University of Milan, Italy
    Dig Liver Dis 33:477-9. 2001
    ..Low levels of hepatitis C virus-RNA found in hepatitis G virus carriers suggest an interaction between these two viruses in immunosuppressed patients...
  12. ncbi Primary prophylaxis of variceal bleeding in cirrhotic patients: a cohort study
    A Dell'Era
    Department of Medical Sciences, University of Milan, IRCCS Ospedale Maggiore Policlinico, Mangiagalli and Regina Elena Foundation, Milan, Italy
    Dig Liver Dis 40:936-43. 2008
    ..However, it has been suggested that these patients may respond poorly to band ligation...
  13. ncbi Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy: a meta-analysis of individual patient data
    C Camma
    Istituto Metodologie Diagnostiche Avanzate, Consiglio Nazionale delle Ricerche, and Cattedra e Unità Operativa di Gastroenterologia, University of Palermo, Palermo, Italy
    Gut 51:864-9. 2002
    ..Retreatment with a combination of alpha interferon (IFN) plus ribavirin of patients with chronic hepatitis C who did not respond to IFN monotherapy has not been assessed in large controlled studies...